Mersana Therapeutics Inc. (MRSN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.52 |
Market Cap | 64.24M |
Revenue (ttm) | 35.07M |
Net Income (ttm) | -75.11M |
EPS (ttm) | -0.6 |
PE Ratio (ttm) | -0.87 |
Forward PE | -3.14 |
Analyst | Buy |
Ask | 0.52 |
Volume | 7,441,314 |
Avg. Volume (20D) | 3,369,658 |
Open | 0.54 |
Previous Close | 0.55 |
Day's Range | 0.52 - 0.55 |
52-Week Range | 0.52 - 6.28 |
Beta | 1.48 |
About MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ...
Analyst Forecast
According to 6 analyst ratings, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1053.85% from the latest price.
Next Earnings Release
Analysts project revenue of $7.64M, reflecting a -28.6% YoY shrinking and earnings per share of -0.16, making a 0.00% YoY.
Why Price Moved
News
2 months ago · seekingalpha.com
Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call TranscriptMersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, C...